Primary Outcomes of the MOTIV BTK Sirolimus-Eluting Bioresorbable Vascular Scaffold for the Treatment of Infrapopliteal Lesions - MOTIV BTK Trial

7 min
Wednesday, August 05, 2026
5:30 PM - 5:37 PM
  • Room
    • Picasso 1-3
share
Back to top